ACSM3

Across TCGA pan-cancer cohorts, ACSM3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACSM3 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACSM3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACSM3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ACSM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.967	0.551	.002	25	view →
PDAC	DFS	Median	All	0.490	0.317	.004	20	view →
LUAD	OS	Median	II,III,IV	1.000	0.433	.005	12	view →
LSCC	DFS	Tertile	II,III,IV	0.578	0.895	.017	4	view →
CCRCC	OS	Median	All	0.984	0.904	.028	3	view →
UCEC	DFS	Median	All	0.924	0.796	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACSM3–HNSC (DFS)

Open the HNSC breakdown →